The Uromigos

401 Episodes

1. Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer

   Published: 3/21/2022
2. Episode 162: Debate - Adjuvant nivolumab for bladder cancer

   Published: 3/14/2022
3. Episode 161: Platinum eligibility in urothelial cancer

   Published: 3/7/2022
4. Episode 160: APCCC - PMSA PET as a diagnostic

   Published: 2/28/2022
5. Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer

   Published: 2/19/2022
6. Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer

   Published: 2/19/2022
7. Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer

   Published: 2/18/2022
8. Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer

   Published: 2/18/2022
9. Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC

   Published: 2/17/2022
10. Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer

    Published: 2/17/2022
11. Episode 153: Overview of PARP inhibition in prostate cancer

    Published: 2/10/2022
12. Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging

    Published: 2/7/2022
13. Episode 151: Bladder Cancer ESMO Guidelines update

    Published: 1/31/2022
14. Episode 150: Comparing the quality of life data in renal trials

    Published: 1/24/2022
15. Episode 149: Treatment-free survival for ipilimumab and nivolumab

    Published: 12/28/2021
16. Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer

    Published: 12/21/2021
17. Episode 147: Renal Cancer Christmas Special

    Published: 12/17/2021
18. Episode 146: Bladder Cancer Christmas Special

    Published: 12/13/2021
19. Episode 145: Prostate Cancer Christmas Special

    Published: 12/6/2021
20. Episode 144: Pembrolizumab for bladder cancer

    Published: 12/2/2021